SQNM ad-hoc 28.07.00 - 500 Beiträge pro Seite

[kapitalix]

SEQUENOM Reaches Purchase and License
Agreement With Leading German Research Center

SAN DIEGO, July 28 /PRNewswire/ -- SEQUENOM, Inc. (Nasdaq: SQNM - news) has reached a MassARRAY(TM)
system purchase and a license agreement with the GSF - National Research Center for Environment and Health, a leading
governmental research institution in Germany, encompassing more than 20 different scientific institutes and more than 1,500
employees. The GSF will use SEQUENOM`s MassARRAY technology to perform large-scale single nucleotide
polymorphism (SNP) validation projects, including candidate gene associations and genetic epidemiology.

``The GSF is a prestigious name in genetic research and we are proud to form this alliance,`` said Karsten Schmidt, Ph.D.,
SEQUENOM`s Managing Director of European Operations. ``It is presumed that the association of SNPs to disease or
the function of genes can differ in various populations. With SEQUENOM`s technology and GSF`s proprietary SNPs and
reference populations, this agreement represents the ability to validate disease association and SNP frequencies in the
German population.``

The robustness, accuracy and high throughput capability of the MassARRAY system will support the GSF`s study of the
distribution of particular chronic diseases in the German population, including asthma, diabetes, cardiovascular disease and
psychiatric disorders. The agreement also allows the GSF to offer SNP analyses as a genotyping center for all of the 16
research centers of the Hermann von Helmholtz Association (HGF).

``A key function of the GSF is to investigate the health status of the population and the environmental risk factors affecting
particular health outcomes,`` said Prof. Dr. Dr. H. E. Wichmann, Head of the Institute of Epidemiology at GSF. ``In order
to score the several million SNPs necessary to associate these variations with the different diseases, we required the
robust, large-scale technology of SEQUENOM`s MassARRAY system.``

The research and development program of the GSF - National Research Center for Environment and Health is committed
to environmental and health protection. The results of the work performed at the GSF provide an important basis in the
issuing of recommended limits in the area of environment and health and are taken up in the decisions of the legislator in
Europe. The GSF performs studies to establish the scientific prerequisites for maintaining human health and understanding
the natural elements necessary for human life. In addition, the GSF is one of the key centers of the German Human
Genome Project. The partners of the GSF are the Federal Republic of Germany represented by the Federal Ministry of
Education and Research and the State of Bavaria.

SEQUENOM is a post-genomics company translating information generated from the map of the human genome into
real-life applications by offering a comprehensive genotyping technology to determine the medical relevance of genetic
variations. SEQUENOM`s distinct competitive advantage is a bottleneck-free SNP analysis solution consisting of its highly
accurate and robust MassARRAY system, an automated assay development process and assay database, the ability to
analyze hundreds of samples in a single reaction and a proven health-based concept for genetic marker validation. As a
leader in SNPs analysis, SEQUENOM offers its powerful technology to customers in diagnostics, pharmacogenomics,
drug development and agricultural biotechnology, while using the MassARRAY technology with a novel scientific strategy
for in-house programs to identify the medical utility of SNPs. SEQUENOM is headquartered in San Diego, California with
offices in Hamburg, Germany and Boston, Massachusetts.

All statements in this press release that are not historical are forward-looking statements within the meaning of the
Securities Exchange Act of 1934, as amended. Such forward-looking statements are subject to factors that could cause
actual results to differ materially for SEQUENOM from those projected. Those factors include risks and uncertainties
relating to technological approaches, product development, manufacturing, market acceptance, cost and pricing of
SEQUENOM products, dependence on collaborative partners, such as the GSF, successful performance under the GSF
and other collaborative agreements, competition, the intellectual property of others, patent protection and other risk factors
discussed from time to time in SEQUENOM`s reports and filings with the Securities and Exchange Commission, including
SEQUENOM`s Annual Report on Form 10-K for the year ended December 31, 1999 and most recent Quarterly Report
on Form 10-Q. SEQUENOM expressly disclaims any obligation or undertaking to release publicly any updates or
revisions to any forward-looking statements contained herein to reflect any change in SEQUENOM`s expectations with
regard thereto or any change in events, conditions, or circumstances on which any such statements are based.

[rainrain]

HAMMER!!

[lovergts]

GEIL und das ist der Kunde: www.gsf.de

[Geldrausch]

@lovergts

äh, ich mag ja nicht so richtig durchblicken aber ist der link den du uns da gegeben hast ironisch oder echt begeistert gemeint ???

Die page sieht aus als hätte sie einer noch kurz vor der meldung mit nem data becker kit hingezimmert.

Muß allerdings zugeben, dass ich nicht genau in den inhalt geschaut habe nur, dass das budget bei 205 mio im Jahr liegt.

Wäre nett, wenn du mir mal aus der patsche helfen könntest.Danke

Gruß
Geldrausch